| Name | Title | Contact Details |
|---|
SyntheMed is a Iselin, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
TAI Diagnostics, Inc. is a biotechnology company focused on providing a non-invasive and highly sensitive diagnostic test to monitor the health of transplanted organs in patients who have received solid organ transplants.
NuVasive® is an innovative medical device company focused on developing minimally disruptive surgical products and procedures for the spine. Our mission is to improve the lives of patients who suffer from debilitating back, neck, or leg pain by creating cutting-edge products and procedures that revolutionize spine surgery through focusing on Speed of Innovation®, Absolute Responsiveness®, and Superior Clinical Results. Through innovative technological advancements, NuVasive has successfully progressed major spine surgery to where many patients have experienced extraordinary results—they are often walking the same day of surgery, experiencing less blood loss, spending less time in the hospital, and going back to work within four to six weeks (versus six months). NuVasive is the third largest medical device company in the global spine industry. We feature more than 90 products spanning lumbar, thoracic, and cervical applications, neuromonitoring services, and a biologics portfolio. Our products have been used in hundreds of thousands of spine surgeries. NuVasive had revenues of $811 million in 2015, including sales in over 30 countries, and employs more than 1,600 people globally. Corporate headquarters are in San Diego, California and Amsterdam, the Netherlands serves as international headquarters. The company has additional offices in the U.S. located in the states of Tennessee, Ohio, Maryland, and California. Internationally, NuVasive has additional offices located Puerto Rico, the United Kingdom, Germany, Italy, Australia, Spain, Singapore, and Japan.
NeuroMetrix Inc. is a Waltham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Headquartered in Milford, Massachusetts, RenalGuard Solutions, Inc. is a medical technology company specializing in innovative technologies for the cardiac and vascular markets. Our newest product, RenalGuard®, has been developed to help prevent the onset of contrast-induced nephropathy (CIN) in at-risk patients undergoing certain imaging procedures. It is already approved for sale in the EU for general fluid balancing. Two investigator-sponsored European studies have demonstrated RenalGuard`s effectiveness at preventing CIN. RenalGuard is being studied in a pivotal trial in the U.S., as required for approval by the FDA. The RenalGuard System™ consists of a closed loop, software-controlled console and single-use sets that physicians and nurses use for automated matched fluid replacement to minimize over- or under-hydration of patients during medical procedures where creating and maintaining high urine outputs is beneficial.